BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a hold rating in a report published on Friday, BidAskClub reports.

A number of other equities research analysts have also recently commented on the company. ValuEngine cut Deciphera Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, August 13th. Cantor Fitzgerald raised their target price on Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a sell rating to a hold rating and set a $26.00 target price on the stock in a research report on Monday, August 5th. Canaccord Genuity restated a buy rating and set a $65.00 target price (up from $50.00) on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Leerink Swann restated a positive rating and set a $29.00 target price (up from $20.00) on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 14th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Deciphera Pharmaceuticals presently has an average rating of Buy and an average target price of $47.90.

Shares of DCPH opened at $36.65 on Friday. The business’s 50-day moving average is $24.22 and its two-hundred day moving average is $24.58. The company has a market capitalization of $1.39 billion, a P/E ratio of -13.00 and a beta of 2.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. Deciphera Pharmaceuticals has a fifty-two week low of $18.55 and a fifty-two week high of $42.99.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.56. The company had revenue of $25.00 million for the quarter, compared to analyst estimates of $20.00 million. Analysts forecast that Deciphera Pharmaceuticals will post -4.19 EPS for the current year.

In related news, major shareholder New Leaf Venture Management Ii sold 350,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $36.42, for a total value of $12,747,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Daniel Lee Flynn sold 148,107 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $40.92, for a total transaction of $6,060,538.44. The disclosure for this sale can be found here. Insiders have sold a total of 535,607 shares of company stock worth $20,283,409 over the last 90 days. Insiders own 7.02% of the company’s stock.

A number of institutional investors have recently modified their holdings of DCPH. Norges Bank purchased a new position in Deciphera Pharmaceuticals in the 4th quarter valued at about $6,974,000. BlackRock Inc. lifted its stake in Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock valued at $34,543,000 after buying an additional 311,870 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Deciphera Pharmaceuticals in the 4th quarter valued at about $4,337,000. Point72 Asset Management L.P. purchased a new position in Deciphera Pharmaceuticals in the 2nd quarter valued at about $4,606,000. Finally, Alps Advisors Inc. purchased a new position in Deciphera Pharmaceuticals in the 2nd quarter valued at about $1,802,000. 59.80% of the stock is currently owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Recommended Story: What is Green Investing?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.